Skip to content 
The Supreme Court on Monday temporarily restored broad access to mifepristone, the abortion pill at the center of one of the country’s most consequential post-Roe legal battles.
The order, signed by Justice Samuel Alito, blocked a lower-court ruling that would have sharply curtailed access to the drug by reinstating an in-person dispensing requirement. For now, patients may continue obtaining mifepristone through certified pharmacies, by mail and through telehealth without an in-person doctor visit.
The stay is narrow and temporary. Reuters reported that Alito’s order gives the justices more time to review emergency requests from Danco Laboratories and GenBioPro, the two companies that make mifepristone products and are defending current FDA access rules.
The stay is set to remain in place until May 11 unless the Court acts again.
Louisiana’s Challenge Put National Access At Risk
View this post on Instagram
The immediate dispute grew out of Louisiana’s lawsuit against the Food and Drug Administration. Louisiana, which has a near-total abortion ban, argues that the FDA’s relaxed mifepristone rules allow abortion pills to reach patients in ways that undermine state law.
A federal appeals court sided with the state on May 1, temporarily blocking mail-order access and reviving older restrictions that required in-person dispensing.
The practical effect would have reached far beyond Louisiana. Mifepristone access through mail and telehealth has become a central route for medication abortion, especially for patients in states where clinics have closed, appointments are scarce or travel is costly.
AP reported that some providers briefly shifted toward misoprostol-only regimens amid the legal uncertainty, a fallback option used in abortion care but often associated with more side effects than the two-drug regimen.
FDA Rules Remain In Place For Now
Mifepristone was first approved by the FDA in 2000. The agency later approved a generic version in 2019. Under current FDA guidance, mifepristone is used with misoprostol to end an intrauterine pregnancy through 10 weeks of gestation. The drug remains subject to a Risk Evaluation and Mitigation Strategy, meaning prescribers and pharmacies must be certified under FDA rules.
The FDA’s current framework allows certified pharmacies to dispense the drug on a prescription from a certified prescriber, including by mail.
That policy became one of the most contested abortion access rules after the Supreme Court overturned Roe v. Wade in 2022, shifting abortion regulation back to the states and intensifying litigation around medication abortion.
Why Mifepristone Has Become A Legal Flashpoint
Medication abortion accounts for most abortions in the United States. Guttmacher has reported that medication abortion made up at least 63% of clinician-provided abortions in states without total bans as of 2023.
That share explains why legal fights over mifepristone now carry consequences comparable to clinic restrictions, waiting periods and state abortion bans.
The Court has already considered a major challenge to mifepristone. In 2024, the justices unanimously ruled that anti-abortion medical groups lacked standing to challenge FDA actions over the drug.
That ruling preserved access at the time, but it did not end efforts by states and abortion opponents to attack the FDA’s authority through different legal routes.
The Next Move Belongs To The Court
For abortion-rights advocates, the temporary stay avoids immediate disruption. For Louisiana and anti-abortion groups, the case remains alive. The Court must now decide whether to extend the stay while litigation continues or allow the Fifth Circuit’s restrictions to take effect.
The legal question is larger than one medication. A ruling against the FDA’s current mifepristone rules could reshape abortion access in states where the procedure remains legal and test how far individual states can go in challenging federal drug regulation.
For now, the country is back where it was before the appeals court intervened: mifepristone remains available through telehealth, mail and certified pharmacies, but only under a temporary Supreme Court order.
